| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Evidence-based
testing
Reducing downstream costs with diagnostic and prognostic testing
At Mayo Clinic, we know the importance of laboratory testing in a patient’s episode of care. Our unique combination of specialized laboratories and cardiology patient care clinics allows us to reduce downstream costs with care-driven testing approaches that produce definitive diagnoses. Our testing can also identify at-risk patients who require earlier intervention or increased surveillance through the most advanced techniques and technologies developed and validated in clinical practice.
Results that matter
We're dedicated to our patients' health and well-being,
and proud of the outstanding outcomes we achieve.
#2
ranked hospital in adult cardiology and heart surgery by U.S. News & World Report
200+
cardiologists on staff at Mayo Clinic
160+
cardiology-specific tests in our
comprehensive test menu
24/7
support from Mayo Clinic physicians and scientists
Clinical utility through targeted panels
Next-generation sequencing (NGS) is an accurate, cost-effective method of identifying inherited variants across numerous genes known to be associated with cardiac disorders.
Novel biomarkers for cardiovascular disease
Standard cardiovascular risk factors only predict about 65% of individuals who will experience a cardiovascular event. As a result, Mayo Clinic physicians are continually investigating novel biomarkers of cardiovascular disease to find those with proven clinical utility, including plasma ceramides, soluble ST2, and Lp-PLA2 activity.
Access to Mayo Clinic expertise
The Cardiovascular Laboratory Medicine Group within Mayo Clinic works to accommodate the growing demand for development, validation, and use of analytes to predict risk for both primary and secondary prevention. Focused on acute-care cardiology, risk stratification, and genomics, the group integrates laboratory cardiology with its colleagues in cardiology, pediatric cardiology, genetics, cardiothoracic and vascular surgery, as well as cerebrovascular specialists in neurology.
Be in the know with MI-HEART ceramides
There is a better way to predict which patients are at the greatest risk and need immediate intervention for heart disease.
The latest
This week’s Research Roundup highlights the effect of inorganic nitrite versus a placebo on exercise capacity among patients with heart failure with preserved ejection fraction.
Genetic testing for cardiovascular disorders is rapidly changing. Recent advancements in technology with next-generation sequencing and the ability to sequence more for less has provided more efficient and cost-effective patient care.
High-sensitivity troponin T is a new assay recently approved by the U.S. Food and Drug Administration. This assay is most often used to evaluate patients with possible acute ischemic heart disease, but it also has a variety of uses in the more chronic setting.
Jeff Meeusen, Ph.D., Co-Director of Cardiovascular Laboratory Medicine, recently had his paper, “Plasma Ceramides—A Novel Predictor of Major Adverse Cardiovascular Events after Coronary Angiography” accepted by the peer-reviewed journal Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB), part of the American Heart Association’s group of journals.
This "Specialty Testing" webinar will discuss what ceramides are and how they link to atherosclerosis and cardiovascular disease processes.